MerLion Pharmaceuticals.drug discovery and development company, engages in the research and development of natural products. It operates through two business units, MerLion Research and MerLion Development. The MerLion Research unit is a contract services business, which provides access to natural product collections by offering sample/extract supply services, extract profiling and standardization, assay development, throughput screening, compound purification and structural identification, biocatalyst isolation, and strain improvement. The MerLion Development unit is progressing finafloxacin, a differentiated antibacterial candidate through phase II clinical trials, which is targeted initially for the eradication of Helicobacter pylori and treatment of urinary tract infections. It also provides portfolio of earlier-stage, preclinical antibacterial, and oncology programmes. The company serves pharmaceutical, industrial biotechnology, agro science, food and flavorings, cosmetics, and personal healthcare companies. MerLion Pharmaceuticals Pte. Ltd. was founded in 2002 and is based in Singapore, Singapore with clinical development operations in Berlin, Germany.


Patents 29show all

  • 12
    A61K - Preparations for medical, dental, or toilet purposes
  • 1
    A23L - Foods, foodstuffs, or non-alcoholic beverages, not covered by subclasses  -
  • 1
    A23V - Indexing scheme relating to foods, foodstuffs or non-alcoholic beverages
  • 1
    A61F - Filters implantable into blood vessels
  • 1
    A61M - Devices for introducing media into, or onto, the body
  • 1
    C07C - Acyclic or carbocyclic compounds
  • 1
    C07D - Heterocyclic compounds
  • 1
    C07H - Sugars
  • 1
    C07K - Peptides

Contact Information

10 Raeburn Park #02-08
Singapore 088702


Total FundingEmployeesLast Funding DateStatus

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2007-03-01$30,000,000Series BZürcher Kantonal Bank, Lacuna
2002-10-30$13,500,000Series AAravis VenturesJAFCO Asia, Temasek Holdings, BioVeda Capital, Novartis Venture Fund, EDBI
2010-10-11$7,000,000Series CRosetta Capital, EDBI, Aurelia Private Equity, Aravis Ventures, HeidelbergCapital Private Equity